Literature DB >> 10914779

Diarrhea as a side effect of mesalamine treatment for inflammatory bowel disease.

F Goldstein1, A J DiMarino.   

Abstract

Tablets of coated 5-aminosalicylate (5-ASA) called mesalazines are among the most widely prescribed preparations for the treatment of colitis, including ulcerative, Crohn's disease (CD), collagenous and lymphocytic colitis, and-to a lesser extent-CD of the small bowel. Mesalamines have, to a large extent, replaced the parent drug sulfasalazine because they produce fewer side effects. Although mesalamines have been known from earlier studies to produce occasional diarrhea, the true incidence of this effect is not known and is not always recognized. We are presenting the cases of five patients in whom oral mesalamines produced severe and persistent diarrhea-made worse by increasing doses of the drug-and intensified the colitis in two. Recognition of the problem is by symptom analysis after careful history taking. Changing the therapeutic regimen or discontinuing the medication is usually required to reverse this potentially debilitating and occasionally life-threatening side effect.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10914779     DOI: 10.1097/00004836-200007000-00014

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  7 in total

Review 1.  Current therapy of inflammatory bowel disease in children.

Authors:  Paul A Rufo; Athos Bousvaros
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 2.  5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease.

Authors:  Yang Cheng; Pierre Desreumaux
Journal:  World J Gastroenterol       Date:  2005-01-21       Impact factor: 5.742

Review 3.  Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.

Authors:  Leon P McLean; Raymond K Cross
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-05-12       Impact factor: 4.481

4.  Mesalamine treatment mimicking relapse in a child with ulcerative colitis.

Authors:  Iva Hojsak; Ana M Pavić; Sanja Kolaček
Journal:  World J Pediatr       Date:  2014-06-28       Impact factor: 2.764

5.  Exacerbation of bloody diarrhea as a side effect of mesalamine treatment of active ulcerative colitis.

Authors:  Yuichi Shimodate; Kunihiro Takanashi; Eriko Waga; Tomoki Fujita; Shinichi Katsuki; Masafumi Nomura
Journal:  Case Rep Gastroenterol       Date:  2011-04-12

6.  A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D).

Authors:  Ching Lam; Wei Tan; Matthew Leighton; Margaret Hastings; Melanie Lingaya; Yirga Falcone; Xiaoying Zhou; Luting Xu; Peter Whorwell; Andrew F Walls; Abed Zaitoun; Alan Montgomery; Robin Spiller
Journal:  Gut       Date:  2015-03-12       Impact factor: 23.059

7.  Mesalamine Intolerance in Three Children with Crohn's Disease.

Authors:  Ceyda Tuna Kirsaclioglu; Zarife Kuloglu; Gonca Ustundag; Aydan Kansu; Erdal İnce; Arzu Ensari; Nurten Girgin
Journal:  Med Princ Pract       Date:  2015-12-02       Impact factor: 1.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.